Literature DB >> 22137612

Assessment of ablative margin by unenhanced magnetic resonance imaging after radiofrequency ablation for hepatocellular carcinoma.

Masahiko Koda1, Shiho Tokunaga, Kennichi Miyoshi, Manabu Kishina, Yuki Fujise, Jun Kato, Tomomitsu Matono, Kinya Okamoto, Yoshikazu Murawaki, Suguru Kakite.   

Abstract

PURPOSE: The aim of this study was to evaluate the feasibility of magnetic resonance imaging (MRI) without a contrast agent to visualize the ablative margin after radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC), compared with enhanced CT.
METHODS: Twenty-five HCCs in 19 patients were treated by RFA. T1-weighted MRI was performed before and after RFA, and the signal intensities of the tumors and surrounding liver tissues were measured. Treatment efficacy was assessed based on three grades: margin (+), a continuous high-intensity rim around the index tumor; margin zero, a partially discontinuous high-intensity rim; margin (-), the tumor extends beyond the high-intensity rim.
RESULTS: Twelve (86%) of fourteen low-intensity tumors on the pre-MRI were visualized as low-intensity tumors on post-MRI, and the ablative margins were visualized as high-intensity rims. Two (67%) of three high-intensity tumors on pre-MRI were visualized as higher-intensity tumors in the high-intensity ablative margin. Because the signal intensities of tumors and surrounding tissues in 14 tumors that were low- or high-intensity tumors on pre-MRI increased to the same extent, the tumors and ablative margin could be distinguished on post images. In 6 (75%) of the 8 iso-intensity tumors on pre-MRI, the ablative margin and tumor could also not be discriminated on post-MRI. The overall agreement between MRI and CT for the ablative margin was good (κ coefficient=0.716, p=0.00002).
CONCLUSION: In 82% of low- or high-intensity tumors on pre-MRI, post-MRI without a contrast agent enabled visualization of the ablative margin as a high-intensity rim, and it was possible to evaluate the ablative margin earlier and easier than with enhanced CT.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22137612     DOI: 10.1016/j.ejrad.2011.11.013

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  11 in total

1.  18F-FDG PET/CT Is an Immediate Imaging Biomarker of Treatment Success After Liver Metastasis Ablation.

Authors:  Francois Cornelis; Vlasios Sotirchos; Elena Violari; Constantinos T Sofocleous; Heiko Schoder; Jeremy C Durack; Robert H Siegelbaum; Majid Maybody; John Humm; Stephen B Solomon
Journal:  J Nucl Med       Date:  2016-02-23       Impact factor: 10.057

2.  A measure to assess the ablative margin using 3D-CT image fusion after radiofrequency ablation of hepatocellular carcinoma.

Authors:  Hui Tang; Yunqiang Tang; Jian Hong; Tiejun Chen; Cong Mai; Peng Jiang
Journal:  HPB (Oxford)       Date:  2014-10-24       Impact factor: 3.647

3.  Radiologic-pathologic correlation of three-dimensional shear-wave elastographic findings in assessing the liver ablation volume after radiofrequency ablation.

Authors:  Katsutoshi Sugimoto; Hisashi Oshiro; Saori Ogawa; Mitsuyoshi Honjo; Takeshi Hara; Fuminori Moriyasu
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

4.  Clinical outcomes of percutaneous radiofrequency ablation for small renal cancer.

Authors:  Keiichi Ito; Shigeyoshi Soga; Kenji Seguchi; Yusuke Shinchi; Ayako Masunaga; Shinsuke Tasaki; Kenji Kuroda; Akinori Sato; Junichi Asakuma; Akio Horiguchi; Hiroshi Shinmoto; Tatsumi Kaji; Tomohiko Asano
Journal:  Oncol Lett       Date:  2017-05-26       Impact factor: 2.967

Review 5.  MRI Assessment of Hepatocellular Carcinoma after Local-Regional Therapy: A Comprehensive Review.

Authors:  Mishal Mendiratta-Lala; William R Masch; Kimberly Shampain; Andrew Zhang; Alexandria S Jo; Sarah Moorman; Anum Aslam; Katherine E Maturen; Matthew S Davenport
Journal:  Radiol Imaging Cancer       Date:  2020-01-31

6.  Feasibility of Extracted-Overlay Fusion Imaging for Intraoperative Treatment Evaluation of Radiofrequency Ablation for Hepatocellular Carcinoma.

Authors:  Yuki Makino; Yasuharu Imai; Takumi Igura; Sachiyo Kogita; Yoshiyuki Sawai; Kazuto Fukuda; Takayuki Iwamoto; Junya Okabe; Manabu Takamura; Norihiko Fujita; Masatoshi Hori; Tetsuo Takehara; Masatoshi Kudo; Takamichi Murakami
Journal:  Liver Cancer       Date:  2016-09-14       Impact factor: 11.740

7.  A Comparative Study of Ablation Boundary Sharpness After Percutaneous Radiofrequency, Cryo-, Microwave, and Irreversible Electroporation Ablation in Normal Swine Liver and Kidneys.

Authors:  Francois H Cornelis; Jeremy C Durack; Simon Y Kimm; Thomas Wimmer; Jonathan A Coleman; Stephen B Solomon; Govindarajan Srimathveeravalli
Journal:  Cardiovasc Intervent Radiol       Date:  2017-05-17       Impact factor: 2.740

8.  Radiofrequency ablation for hepatocellular carcinoma: the relationship between a new grading system for the ablative margin and clinical outcomes.

Authors:  Hiroki Nishikawa; Yukio Osaki; Eriko Iguchi; Haruhiko Takeda; Fumihiro Matsuda; Jun Nakajima; Azusa Sakamoto; Keiichi Hatamaru; Sumio Saito; Akihiro Nasu; Ryuichi Kita; Toru Kimura
Journal:  J Gastroenterol       Date:  2012-10-12       Impact factor: 7.527

9.  Three-dimensional quantitative assessment of ablation margins based on registration of pre- and post-procedural MRI and distance map.

Authors:  Soichiro Tani; Servet Tatli; Nobuhiko Hata; Xavier Garcia-Rojas; Olutayo I Olubiyi; Stuart G Silverman; Junichi Tokuda
Journal:  Int J Comput Assist Radiol Surg       Date:  2016-04-02       Impact factor: 2.924

10.  Enhanced primary tumor delineation in pancreatic adenocarcinoma using ultrasmall super paramagnetic iron oxide nanoparticle-ferumoxytol: an initial experience with histopathologic correlation.

Authors:  Sandeep S Hedgire; Mari Mino-Kenudson; Azadeh Elmi; Sarah Thayer; Carlos Fernandez-del Castillo; Mukesh G Harisinghani
Journal:  Int J Nanomedicine       Date:  2014-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.